News

Talaris Therapeutics plans to initiate a Phase 1/2a trial to test its investigational cell therapy, FCR001, in people with diffuse cutaneous systemic sclerosis (dcSSc), the company has announced. The trial follows the recent approval of an investigational new drug application for FCR001 by the U.S.

Obstructive sleep apnea (OSA) is associated with an increased risk of pulmonary hypertension in people with scleroderma, a study suggests. The study, “Impact of concomitant obstructive sleep apnea on pulmonary involvement and main pulmonary artery diameter in adults with scleroderma,” was published in the journal Sleep…

The American College of Rheumatology Combined Response Index in diffuse cutaneous systemic sclerosis (ACR CRISS) appears to be a consistent and reliable measure of how these patients feel and function, according to data recently presented by Corbus Pharmaceuticals. Notably, the research suggests that this composite measure, which is frequently used…

Orencia (abatacept) — an approved medication for juvenile idiopathic arthritis and other inflammatory conditions — is a safe and effective treatment for localized scleroderma in both children and adults, according to a case series and review study. “This is the first published paper on abatacept as a…

A form of ultrasound imaging called shear-wave elastography (SWE) is more sensitive for assessing changes in skin stiffness over time in scleroderma (SSc) patients than the current gold standard measure, a study suggested. Because a lessening in skin stiffness was also observed in healthy people, skin changes…

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for a disease that few people — sometimes even physicians — have heard of is challenging on its own merit.